Paul Sutton

US Patent:

7247746, Jul 24, 2007

Filed:

Apr 14, 2003

Appl. No.:

10/510927

Inventors:

Paul Allen Sutton - Parsippany NJ, US

Assignee:

Novartis, AG - Basel

International Classification:

C07C 229/46
C07C 235/82

US Classification:

562450, 562444, 562445

Abstract:

New crystal forms of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine, also known asnateglinide, may be produced by dissolving nateglinide in any of its forms, including solvates, in an organic solvent to form a solution followed by precipitation of nateglinide from the solution, and isolating and drying the precipitated crystal form of nateglinide. The precipitation of nateglinide may be induced either by cooling the solution, or by addition of another solvent which is miscible with the first solvent but in which nateglinide is only poorly soluble, or by combination of the two. Depending on the solvent a specific crystal form of nateglinide may be obtained, e. g. , the R′-type crystal form of nateglinide produced by the described method has a different melting point, infra red spectra and X-ray diffraction patterns from the previously known crystal forms of nateglinide.

US Patent:

8163904, Apr 24, 2012

Filed:

Jul 18, 2006

Appl. No.:

11/995898

Inventors:

Paul W Manley - Arlesheim, CH
Wen-Chung Shieh - Berkeley Heights NJ, US
Paul Allen Sutton - Parsippany NJ, US
Piotr H Karpinski - Lincoln Park NJ, US
Raeann Wu - Pine Brook NJ, US
Stéphanie Monnier - Raedersheim, FR
Jörg Brozio - Basel, CH

Assignee:

Novartis AG - Basel
Novartis Pharma GmbH - Vienna

International Classification:

C07D 401/14
A61K 31/506
A61P 35/00

US Classification:

544331, 514275

Abstract:

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

US Patent:

8343984, Jan 1, 2013

Filed:

Jul 18, 2006

Appl. No.:

11/995906

Inventors:

Paul W Manley - Arlesheim, CH
Wen-Chung Shieh - Berkeley Heights NJ, US
Paul Allen Sutton - Parsippany NJ, US
Piotr “Peter” H Karpinski - Lincoln Park NJ, US
Raeann Wu - Pine Brook NJ, US
Stéphanie M. Monnier - Raedersheim, FR
Jörg Brozio - Basel, CH

Assignee:

Novartis AG - Basel
Novartis Pharma GmbH - Vienna

International Classification:

A01N 43/54
A61K 31/505
C07D 239/02

US Classification:

514269, 544316

Abstract:

Polymorphic forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

US Patent:

8389537, Mar 5, 2013

Filed:

Mar 13, 2012

Appl. No.:

13/419132

Inventors:

Paul W Manley - Arlesheim, CH
Wen-Chung Shieh - Berkeley Heights NJ, US
Paul Allen Sutton - Parsippany NJ, US
Piotr H Karpinski - Lincoln Park NJ, US
Raeann Wu - Pine Brook NJ, US
Stéphanie Monnier - Raedersheim, FR
Jörg Brozio - Basel, CH

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/506
A61P 35/00
C07D 401/14

US Classification:

514275, 544331

Abstract:

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

US Patent:

8415363, Apr 9, 2013

Filed:

Aug 3, 2012

Appl. No.:

13/565913

Inventors:

Paul W Manley - Arlesheim, CH
Wen-Chung Shieh - Berkeley Heights NJ, US
Paul Allen Sutton - Parsippany NJ, US
Piotr “Peter” H Karpinski - Lincoln Park NJ, US
Raeann R Wu - Pine Brook NJ, US
Stéphanie M Monnier - Raedersheim, FR
Jörg Brozio - Basel, CH

Assignee:

Novartis AG - Basel

International Classification:

A01N 43/54
A61K 31/505
C07D 239/02

US Classification:

514269, 544316

Abstract:

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

US Patent:

8580806, Nov 12, 2013

Filed:

Jan 22, 2013

Appl. No.:

13/747052

Inventors:

- Basel, CH
Wen-Chung Shieh - Berkeley Heights NJ, US
Paul Allen Sutton - Parsippany NJ, US
Piotr H Karpinski - Lincoln Park NJ, US
Raeann Wu - Pine Brook NJ, US
Stéphanie Monnier - Raedersheim, FR
Jörg Brozio - Basel, CH

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/506
A61P 35/00
C07D 401/14

US Classification:

514275, 544331

Abstract:

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

US Patent:

20050234129, Oct 20, 2005

Filed:

Mar 10, 2003

Appl. No.:

10/507255

Inventors:

Paul Sutton - Parsippany NJ, US
Richard Vivilecchia - Rockaway NJ, US
David Parker - West Milford NJ, US
Marilyn De La Cruz - Matawan NJ, US

International Classification:

A61K031/7008
A61K031/198
C07C233/81
A61K031/205

US Classification:

514563000, 562450000, 514062000, 536055300

Abstract:

The present invention relates to salts of organic acid, in particular salt of nateglinide, combined preparations comprising one or more salts of nateglinide and, optionally, one or more additional ingredients and the use thereof in pharmaceutical compositions for preventing or treating diabetes, cardiovascular diseases, or conditions associated therewith.

US Patent:

20060035941, Feb 16, 2006

Filed:

Jun 12, 2003

Appl. No.:

10/517874

Inventors:

Guang-Pei Chen - Livingston NJ, US
Prasad Kapa - Parsippany NJ, US
Paul Sutton - Parsippany NJ, US

International Classification:

A61K 31/404
C07D 209/04

US Classification:

514359000, 514415000, 548510000

Abstract:

The present invention provides calcium salts of indole derived statins of the formula (IA) wherein R, is alkyl, cycloalkyl or aralkyl; R, Rand Rare independently hydrogen, halogen or alkyl; Rand Rare independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3position is in the R-configuration and at the 5position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; as obtainable by the methods of the present invention. More specifically, the invention provides a calcium salt of formula (IA) wherein R, is isopropyl, Ris fluorine and R, R, Rand Rare hydrogen, designated herein as Fluvastatin calcium, in a highly crystalline form. Furthermore, the present invention is directed to methods for the preparation of the crystalline Fluvastatin calcium, and to pharmaceutical compositions comprising the crystalline form.